RDFA
JAZZ icon

Ritter Daniher Financial Advisory’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ritter Daniher Financial Advisory’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-57
Closed -$7.51K – 617
2025
Q3 		$7.51K Buy
+57
New +$6.84K ﹤0.01% 367

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Ritter Daniher Financial Advisory's JAZZ Position: Q4 2025 in Review

Ritter Daniher Financial Advisory sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 57 shares — an estimated $7.51K sold.

Ritter Daniher Financial Advisory first reported a position in JAZZ in Q3 2025 and held it in 1 quarter. The position peaked at $7.51K in Q3 2025. 576 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

  • Ritter Daniher Financial Advisory reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Ritter Daniher Financial Advisory sold 57 Jazz Pharmaceuticals shares in Q4 2025, an estimated $7.51K.
  • Ritter Daniher Financial Advisory first reported a position in Jazz Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Ritter Daniher Financial Advisory's Jazz Pharmaceuticals position peaked at $7.51K in Q3 2025.
  • 576 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on Ritter Daniher Financial Advisory's 13F filing for Q4 2025, filed 10 Feb 2026.